PDE5 Inhibitors
- PMID: 31751033
- Bookshelf ID: NBK549843
PDE5 Inhibitors
Excerpt
The discovery of phosphodiesterase 5 inhibitors (PDE5 inhibitors) for causing the erection of the penis was accidental, noticed as a side effect while being administered to investigate their ability to treat hypertension and angina. Phosphodiesterase 5 Inhibitors (PDE5Is) are now widely used in the management of erectile dysfunction. This activity illustrates the indications, mechanism of action, administration, adverse drug reactions, contraindications, monitoring, and toxicity of PDE5 inhibitors. This activity also demonstrates the importance of an interprofessional team in the treatment of patients with erectile dysfunction, high altitude illness, lower urinary tract symptoms, angina, or pulmonary hypertension, using PDE5 inhibitors (i.e., sildenafil, tadalafil, vardenafil, etc.)
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999 Jul;84(1):50-6. - PubMed
-
- Xu Y, Liu Y, Liu J, Qian G. Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications. High Alt Med Biol. 2014 Apr;15(1):46-51. - PubMed
-
- Hong JH, Kwon YS, Kim IY. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):183-192. - PubMed
-
- Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, Rwabasonga B, Risk MC, Wilt TJ. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol. 2017 Apr;71(4):570-581. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources